



**Figure 4:** Risk-benefit analysis. summary of the evidence provided by the data in favor of benefit (red), as opposed to risk (blue). A value larger than one means a favorable benefit-risk ratio. A: Docetaxel; B: Nimotuzumab; C: Racotumomab.